Viral vectors
Introduction to Viral Vectors for Gene Therapy
April Stanley, MS MBA
Nice Insight
NI-8-26-MA41Aug 27, 2026
mRNA / Analytics
Analytical Landscape of Viral Vectors
April Stanley, MS MBA
Nice Insight
NI-8-26-MA44Aug 27, 2026
Vaccines
The Next Generation of Vaccine Platforms
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-01Aug 3, 2026
Pathfinder
Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?
Nice Insight
PAO-26-PF-11Jun 12, 2026
CGT Patents
The Patent Landscape and its Implications: Cell and Gene Therapies
April Stanley, MS MBA
Nice Insight
NI-06-26-04Jun 1, 2026
Continuous VV
The Stepwise Future of Continuous Viral Vector Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-12Jun 1, 2026
Pathfinder
AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?
Nice Insight
PAO-26-PF-09May 29, 2026
cell therapy
State of the Cell and Gene Therapy Market
James Grote
Nice Insight
PAO-10-022-NI-01Oct 11, 2022
Column: M&A
Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
Nigel Walker
Nice Insight
PAO-06-022--NI-12Jun 24, 2022
YEAR REVIEW
2021 Roundup: The Year of Cell and Gene Therapy
David Alvaro, Ph.D.
Pharma's Almanac
PA734Dec 20, 2021